

第十二屆胰臟癌國際研討會暨林炳文教授紀念演講會

The 12th International Pancreatic Cancer Conference & Commemorative Lecture of Pin-Wen Lin

日期：2019年7月5日（星期五） 14:10~17:00

地點：高雄醫學大學附設中和紀念醫院啟川大樓六樓第二講堂

Time	Topic	Speaker	Moderator
13:30~ 14:10	Registration		
14:10~ 14:30	Opening: 1. Dean of College of Medicine, NCKU: Jang-Yang Chang (張俊彥) 2. Chief of Taiwan Gastrointestinal Surgery Society: King-Teh Lee (李金德) 3. Chief of Taiwan Pancreas Society: Ta-Sen Yeh (葉大森) 4. Distinguished Investigator and Director, National Institute of Cancer Research, NHRI: Li-Tzong Chen (陳立宗)		
14:30~ 15:20	Annual Awards for Memory Lecture of Pin-Wen Lin: Isolated pancreatoduodenectomy using Nakao mesenteric approach	Akimasa Nakao	Lein-Ray Mo (牟聯瑞) Min-Fu Chen (陳敏夫)
15:20~ 15:50	Young Investigator Award of Hsu-Yuan Education Foundation: Rab37 mediates osteopontin secretion to promote pancreatic tumorigenesis via exocytotic and exosomal pathways	Ya-Chin Hou (侯雅琴)	Yan-Shen Shan (沈延盛) Yu-Wen Tien (田郁文)
15:50~ 16:00	Coffee break		
Management of Pancreatic Cancer			
16:00~ 16:30	Treatment strategy for borderline resectable pancreatic cancer	Masafumi Ikeda	Jaw-Town Lin (林肇堂)
16:30~ 17:00	The experience of EUS-FNA of pancreatic cancer	Hiroshi Imaoka	Tsann-Long Hwang (黃燦龍)

學會教育積分：(申請中)

台灣外科醫學會

台灣消化系外科醫學會

中華民國醫用超音波學會

台灣內視鏡外科醫學會

中華民國癌症醫學會

B類 7分

10分

台灣內科醫學會

台灣消化系內視鏡醫學會

台灣消化系醫學會

台灣臨床腫瘤醫學會

台灣放射腫瘤學會

第十二屆胰臟癌國際研討會暨林炳文教授紀念演講會
The 12th International Pancreatic Cancer Conference &
Commemorative Lecture of Pin-Wen Lin

日期：2019年7月6日(星期六) 1210~1720

地點：高雄醫學大學附設中和紀念醫院啟川大樓六樓

Time	Topic	Speaker	Moderator
12:00-13:30	報 到		
12:10-12:35	Lunch symposium: The experience of Onivyde in Japan 第一會議室	Tatsuya Ioka	Yi-Yin Jan (詹益銀)
12:35-13:00	Lunch symposium The experience of Onivyde in Taiwan 第一會議室	Yan-Shen Shan (沈延盛)	Chia-Jui Yen (顏家瑞)
13:40-13:45	Opening 李金德 理事長 致詞		
13:45-13:50	Welcome address 郭功楷 會長 致詞		
Pancreas Section 第二講堂			
13:50-14:30	Neoadjuvant chemotherapy in resectable pancreatic cancer	David K. Chang	Yi-Ming Shyr (石宜銘) Ta-Sen Yeh (葉大森)
14:30-15:00	The optimal surgical extent for pancreatic cancer based on RCT	Jin-Young Jang	
15:00-15:30	From traditional pancreaticoduodenectomy to laparoscopic/ Robotic pancreaticoduodenectomy. The tips for success.	Ying-Jui Chao (趙盈瑞)	
15:30-15:50			
15:50-16:20	Adjuvant chemotherapy for pancreatic cancer	Li-Tzong Chen (陳立宗)	King-Teh Lee (李金德) Jen-Shi Chen (陳仁熙)
16:20-16:50	The first line chemotherapy for advanced and metastatic pancreatic cancer	Li-Yuan Bai (白禮源)	
16:50-17:20	Second-line chemotherapy for advanced and metastatic pancreatic cancer	Tatsuya Ioka	

主辦單位：成大醫院、台灣胰臟醫學會、國衛院癌症研究所、財團法人成杏醫學文教基金會、林炳文教育基金、財團法人徐燕教育基金會、台灣消化外科醫學會

CURRICULUM VITAE

NAME / CURRENT APPOINTMENTS

Akimasa Nakao, MD, PhD, FACS

Professor Emeritus, Nagoya University

President, Nagoya Central Hospital



OFFICE

Central Japan Railway Company

NAGOYA CENTRAL HOSPITAL

Address: 3-7-7 Taiko, Nakamura-ku, Nagoya 453-0801, JAPAN

Phone: +81-52-452-6683, Fax: +81-52-452-3190

E-mail: akimasa.nakao@jr-central.co.jp /nakaoaki@med.nagoya-u.ac.jp

EDUCATION

1973 MD, Nagoya University School of Medicine, Nagoya, Japan

1984 PhD, Nagoya University Graduate School of Medicine, Nagoya, Japan

ACCADEMIC APPOINTMENTS

1980 Staff member, Department of Surgery II, Nagoya University

1983 Assistant Professor, Department of Surgery II, Nagoya University

1987 Lecturer, Department of Surgery II, Nagoya University

1989-1990 Clinical research fellow, University of Pittsburgh, Department of Surgery

1992-1999 Associate Professor, Department of Surgery II, Nagoya University

1999-2011 Professor and Chairman, Department of Gastroenterological surgery (Surgery II), Nagoya University

2011-present Professor Emeritus, Nagoya University, President, Nagoya Central Hospital

MEMBESHIP OF INTERNATIONAL SOCIETIES

IASGO, ACS, ISS, ISDS, IAP, SSO, IHPBA, UICC Professional Education Committee, ISSO, Valencia Royal Medial Academy

HONORARY MEMBESHIP

Bulgarian Surgical Society (2006), Serbian Medical Society (2008), Royal College of Surgeons of Thailand (2008), Egyptian Society of Surgeons (2010), European Surgical Association (2011), French Surgical Association (2011), American Society of Clinical Oncology (2014), Japan Surgical Society (2012), Japan Pancreas Society (2013), Japan Society of Clinical Oncology (2013), Spanish Society of Surgeons (2015), Serbian Medical Academy (2016), American college of surgeons (2018)

MAJOR FIELDS OF INTEREST

1. Pancreatic cancer 2. Bile duct carcinoma 3. Hepatocellular carcinoma

ACHIEVEMENTS

International Book Chapter: 20

International Journal Articles: 557

Speaker at World Congresses, meetings and lectures (First Author): 283

Curriculum Vitae

侯雅琴 Ya-Chin Hou

Institute of Clinical Medicine, College of Medicine, National Cheng Kung University

Address: Room 06016, 6F, No. 138, Sheng-Li Road, East Dist., Tainan City, Taiwan

Tel: 886-6-2353535 ext. 3116

E-mail: yachi2016@yahoo.com.tw




Highest Education

Ph.D, Institute of Basic Medical Science, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Publications


1. **Hou YC**, Hsieh MH, Tung HL, Wang HC, Shan YS. Low CD8⁺ T cell infiltration and high PD-L1 expression are associated with level of CD44⁺/CD133⁺ cancer stem cells and predict an unfavorable prognosis in pancreatic cancer. *Cancers* 2019; 11(4): 541.
2. **Hou YC**, Wang CJ, Chao YJ, Chen HY, Wang HC, Tung HL, Lin JT, Shan YS. Elevated serum Interleukin-8 level correlates with cancer-related cachexia and sarcopenia: an indicator for pancreatic cancer outcomes. *Journal of Clinical Medicine* 2018; 7(12): 502.
3. Chen CW, Cheng TJ, Ho CH, Wang JJ, Weng SF, **Hou YC**, Cheng HC, Chio CC, Shan YS, Chang WT. Increased the risk of brain cancer incidence in stroke patients: A clinical case series, population-based and longitudinal follow-up study. *Oncotarget* 2017; 8(65): 108989-108999.
4. Wang HC*, Chen CW*, Yang CL*, Tsai IM, **Hou YC**, Chen CJ, Shan YS. Tumor-associated macrophages promote epigenetic silencing of gelsolin through DNA methyltransferase 1 in gastric cancer cells. *Cancer Immunology Research* 2017; 5(10): 885-897.
5. Hsu YH, Li HH, Sung JM, Chen WY, **Hou YC**, Weng YH, Lai WT, Wu CH, Chang MS. Interleukin-20 targets podocytes and is upregulated in experimental murine diabetic nephropathy. *Experimental and molecular medicine* 2017; 49(3): e310.
6. Wang HC*, Li TY*, Chao YJ, **Hou YC**, Hsueh YS, Hsu KH, Shan YS. KIT exon 11 codons 557-558 deletion mutation promotes liver metastasis through the CXCL12/CXCR4 axis in gastrointestinal stromal tumors. *Clinical Cancer Research* 2016; 22(14): 3477-87.
7. Chen CJ, **Hou YC**, Wang HC, Shieh CC, Shan YS. The role of NADPH oxidase 2 on M2 tumor-associated macrophages differentiation in pancreatic cancer progression. *European Journal of Immunology* 2016; 46(S1): 192.
8. Yang MC*, Wang HC*, **Hou YC***, Tung HL, Chiu TJ, Shan YS. Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. *Molecular Cancer* 2015; 14(1): 179. (*co-first author)
9. **Hou YC**, Huang CF, Wang HC, Wu Y, Shan YS. Therapeutic efficacy of spleen-derived mesenchymal stem cells in mice with acute pancreatitis. *Journal of Stem Cell Research Therapy* 2015; 5(12): 318.
10. **Hou YC**, Chen HY, Tung HL, Wang HC, Chao YJ, Shan YS. Interleukin-8 is a prognostic biomarker in pancreatic cancer cachexia. *Pancreatology* 2015; 15(3): S99-S100.
11. **Hou YC**, Chao YJ, Tung HL, Wang HC, Shan YS. Coexpression of CD44-positive/ CD133-positive

- cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. *Cancer* 2014; 120(17): 2766-2777.
12. Wang HC*, **Hou YC***, Shan YS. The advances in pancreatic cancer stem cells, tumor-associated macrophages, and their interplay. *Cancer Cell & Microenvironment* 2014; 1(e304):1-14. (*co-first author)
 13. Wang WY*, Hsu CC*, Wang TY*, Li CR*, **Hou YC**, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MT, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL, Chen LT, Tsai KK. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. *Gastroenterology* 2013; 145(5): 1110-1120.
 14. Hsu YH, Li HH, Sung JM, Chen WT, **Hou YC**, Chang MS. Interleukin-19 mediates tissue damage in murine ischemic acute kidney injury. *PLoS One* 2013; 8(2): e56028.



Curriculum Vitae

Name	Masafumi Ikeda
Current Position, Department, Affiliation	Chief, Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East
Areas of interest	Medical oncology of hepatobiliary and pancreatic cancer.
Educational and Career Experiences	<p>Third department of Internal Medicine, Kumamoto University School of Medicine, Trainee, 1994-1995.</p> <p>Internal Medicine, Minamata City General Hospital and Medical Center, Trainee, 1995-1996.</p> <p>Internal Medicine, National Cancer Center Hospital, Resident, 1996-1999.</p> <p>Hepatobiliary and Pancreatic Oncology division, National Cancer Center Hospital, Chief resident, 1999-2001.</p> <p>Third department of Internal Medicine, Kumamoto University School of Medicine, Medical staff, 2001-2002.</p> <p>Hepatobiliary and Pancreatic Oncology division, National Cancer Center Hospital, Medical staff, 2002-2008.</p> <p>Department of hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Section head, 2008-</p> <p>Department of hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chief, 2011-</p>
Honors and Awards	<ul style="list-style-type: none"> • Asia Pacific Association for the study of Liver Meeting 2002 Young Investigators Award. • Journal of Gastroenterology 2006 Incentive award



CURRICULUM VITAE

NAME: Hiroshi Imaoka, M.D., Ph.D.

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East

PRESENT ADDRESS:

OFFICE: 6-5-1 Kashiwano-ha, Kashiwa, Chiba, Japan, ZIP 277-8577

TEL: +81-47-133-1111

FAX: +81-47-131-9960

TRAINING:

M.D., 2000 Kobe University, Japan

Major Field: Medicine

Ph.D., 2009 Shimane University, Japan

Major Field: Gastroenterology


Dissertation Title: Exacerbation of Indomethacin-Induced Small Intestinal Injuries in *reg*
I-Knockout Mice

LICENSURE and CERTIFICATION

National Board of Medicine, Registration No. 407999

Japanese Board of Gastroenterological Endoscopy Society No. 20080052

Japanese Board of Society of Gastroenterology No. 32585



English Name : Yan-Shen Shan

(Also name Yen-Sheng Shen)

Birth Day: 1963, Mar. 17

Chinese Name 中文姓名：沈延盛

生日：中華民國 52 年 3 月 17 日

Specialty (專長) and Study Field:

Gastrointestinal Medicine, Surgical Oncology,
Cancer biology (tumor microenvironment),
Regeneration medicine (liver and pancreas regeneration),
Traumatology, Surgical nutrition and infection

Current Position:

2017.08- Director, Institute of Clinical Medicine, National Cheng Kung University

2016.08- Director, Department of Clinical Medical Research, National Cheng Kung University Hospital

2010.10- Convener of UGI Cancer, National Cheng Kung University Hospital

Education:

2006.11-2007.08 Visiting Scholar of University of Pennsylvania and Thomas Jefferson Hospital, USA

1998.09-2004.06 Ph.D., Clinical Medicine, National Cheng Kung University

1988.09-1993.06 M.D., School of Medicine, National Cheng Kung University

1981.09-1985.06 B.D., Department of Rehabilitation Medicine, National Taiwan University

Research Experience:

2016.8- Distinguished Professor, Institute of Clinical Medicine, National Cheng Kung University

2012.8- Professor, Institute of Clinical Medicine, National Cheng Kung University

2012.8- Professor, Department of Surgery, National Cheng Kung University

2010.08-2016.06 Chief of Division of Trauma, Department of Surgery, NCKUH

2010.8- Associate professor, Institute of Clinical Medicine, National Cheng Kung University

2008.8- Clinical Associate professor, Department of Surgery, National Cheng Kung University

2002.8- Clinical Assistant professor, Department of Surgery, National Cheng Kung University

1998.8- Visiting Surgeon, Department of Surgery, National Cheng Kung University Hospital

Services:

1. Director, Institute of Clinical Medicine, National Cheng Kung University (Aug, 2017-present).
2. Director, Department of Clinical Medical Research, National Cheng Kung University Hospital (Aug, 2016-present).
3. Distinguished Professor, Institute of Clinical Medicine, College of Medicine, National Cheng Kung University 2016.
4. Supervisors, The 1st to 10th International Pancreatic Cancer Conference, Commemorative Lecture of Pin-Wen Lin and 2017 Cancer Biology Symposium (2008-2017).
5. Member of a council, International Association of Surgeon and Gastrpenterologists.
6. Member of a council, The American Society of Clinical Oncology.
7. Member of a council, Asia-Ocean Pancreatic Association (AOPA).
8. Member of a council, Formosan Association of Surgery.

9. Member of a council, Taiwan Surgical Society of Gastroenterology.
10. Member of a council, Taiwan Pancreas Society.
11. Member of a council, Taiwan Society of Endoscopic Surgery.
12. Member of a council, Taiwan Oncology Society.
13. Member of a council, Taiwan Society for Metabolic and Bariatric Surgery.
14. 中華民國考試院典試外科學出題委員(2016, 2017)

Awards and Honors:

1. 2018 Cancer Outstanding Research Award of Chien-Tien Hsu Cancer Research Foundation (107年度徐千田癌症研究傑出獎)
2. 2017 The best top three researcher of NCKUH.
3. 2017 The Best Paper Award of Cheng-Hsing Medical Foundation.
4. 2016 The Best Paper Award of College of Medicine, National Cheng Kung University.
5. 2016 The Best Paper Award of International College of Surgeons, 1st.
6. 2016 Encouraging Publishing International Top Journal of National Cheng Kung University (國立成功大學鼓勵發表國際頂尖期刊獎勵, Lancet).
7. 2016 Travel award of K. T. Li Foundation of the Development of Science and Technology (李國鼎基金會補助國際會議).
8. 2015 Excellence Attending physician of National Cheng Kung University Hospital (成大醫院104年度傑出主治醫師).
9. 2015 The Annual Best Researcher of the Department of Surgery of National Cheng Kung Medical Center.
10. 2014 The Best Paper Award of International College of Surgeons (2014), excellent paper.
11. 2014 The 51th JSSMN Travel award (instructor).
12. 2014 Merit award of the 11th Asian Clinical Oncology Society (ACOS).
13. 2014 The Annual Best Researcher of the Department of Surgery of National Cheng Kung Medical Center.
14. 2013 Paper Award of International College of Surgeons, 1st.
15. 2013 The Annual Best Researcher of the Department of Surgery of National Cheng Kung Medical Center.
16. 2012 Ann Surg Association, Video competition Award, 2nd (runner-up), (Instructor).
17. 2012 The Best Paper Award of International College of Surgeons, 1st.
18. 2011 Abstract award, 2nd (Runner-up) in the 9th Asia-Pacific Oncology Summit.
19. 2011-2017 Ministry of Science and Technology Talent Subsidy Incentives by Faculty Members and Researchers (榮獲科技部100-105年度補助大專校院獎勵特殊優秀人才措施獎勵).
20. 2010 Paper Award of International College of Surgeons, 4rd (Instructor).
21. 2009 46th JSSMN Travel award (Instructor).
22. 2009 Paper Award of International College of Surgeons (Instructor).
23. 2008 Post of Distinction of Digestive Disease Week, USA.
24. 2008 The Best Paper of the year of National Cheng Kung University Hospital, 2nd (Instructor).
25. 2008 National Cheng Kung University Research Incentives category B (成功大學研究獎勵 B 類).
26. 2007-2015 The Annual Best Researcher of the Department of Surgery of National Cheng Kung

Medical Center.

27. 2007 Paper Award of International College of Surgeons.
28. 2006 The Best Oral Paper presentation of Taiwan Surgical Society of Gastroenterology (Instructor).
29. 2004 Post Award of Joint meeting of the 11th meeting of International Association of Pancreatology and the 35th Annual meeting of the Japan Pancreas Society.
30. 2003 The Best Paper of the year of National Cheng Kung University Hospital.



Jang, Jin-Young

Department

Hepatobiliary and Pancreatic Surgery

Pancreatic and Biliary Cancer Center Surgery

Specialty

Gallbladder cancer, Pancreatic malignancy, Suspicion of pancreaticobiliary cancer, Biliary malignant disease, Pancreas benign disease, Pancreatic cancer, Biliary cancer, Duodenum, Duodenal cancer

Background

Professor Jin-Young Jang graduated from Seoul National University and has done his residency training in the Department of General Surgery, where he continued his fellowship training in biliary tract and pancreas surgery at Seoul National University Hospital (SNUH). He worked at MD Anderson Cancer Center, Texas, USA as assistant professor and He is currently the professor in the Department of Surgery at Seoul National University College of Medicine. He is one of world famous pancreas and biliary surgeon. He is actively working as a member of clinical guideline for pancreas and biliary disease representing Korea. He is also currently the Director of clinical services at Seoul National University Cancer Hospital. Professor Jang's clinical practice focuses mainly on pancreatic cancer, gallbladder cancer, and biliary tract cancer. He is also expert surgeon in minimally invasive surgery such as laparoscopic and robotic surgery.

Education & Professional Activities

1999. 3. ~ 2001. 8. Seoul National University College of Medicine / Ph.D.

1997. 3. ~ 1999. 2. Seoul National University College of Medicine / M.S.

1987. 3. ~ 1994. 2. Seoul National University College of Medicine /

CURRICULUM VITAE



Ying-Jui Chao, MD

Assistant professor of general surgery
National Cheng-Kung University Hospital
No.138,Sheng Li Road,Tainan, Taiwan 704, R.O.C.
TEL : (06)2353535 Ext. 5182 FAX : 06-2766676

Medical Education

1996~2003- M.D., College of Medicine Taipei Medical University, Taipei, Taiwan

Postdoctoral Training

2004.4~2006.7- Resident, Department of Surgery, National Cheng Kung University Hospital

2006.8~2007.7- Resident, Division of General Surgery, Department of Surgery, National Cheng Kung University Hospital

2007.8~2009.7- Chief Resident, Division of General Surgery, Department of Surgery, National Cheng Kung University Hospital

Medical Licensures

Diploma, Board of Surgery (Taiwan)

Diploma, Board of Digestive Surgery (Taiwan)

Diploma, Board of Endoscopic Surgery (Taiwan)

Hospital Appointment

2009.8~2010.7- Attending Surgeon, Division of General Surgery, Department of Surgery, Tainan Municipal Hospital

2010.8~2012.7- Attending Surgeon, Division of General Surgery, Department of Surgery, National Cheng Kung University Hospital, Dou-Liou branch

2012.8~ Attending Surgeon, Division of General Surgery, Department of Surgery, National Cheng Kung University Hospital

2016.8~ Assistant professor, Division of General Surgery, Department of Surgery, National Cheng Kung University Hospital

Honors and Awards

2012 2nd place, Award of Best Video competition of endoscopic surgery, 71th Annual meeting of Taiwan Surgical Association

2016 Best paper award of Taiwan association for endoscopic surgery, 75th Annual meeting of Taiwan Surgical Association

Referred paper

- 1.Wang HC, Li TY, Chao YJ, Hou YC, Hsueh YS, Hsu KH, Shan YS. KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors. *Clin Cancer Res.* 2016 Jul 15;22(14):3477-87
- 2.Wu CL, Chao YJ, Yang TM, Chen YL, Chang KC, Hsu HP, Shan YS, Lai MD. Dual role of CD44 isoforms in ampullary adenocarcinoma: CD44s predicts poor prognosis in early cancer and CD44v is an indicator for recurrence in advanced cancer. *BMC cancer.* 2015 Nov 16;15(1):903. doi: 10.1186/s12885-015-1924-3.
3. Chang-Ni Lin, Chih-Jung Wang, Ying-Jui Chao, Ming-Derg Lai, Yan-Shen Shan . The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. *BMC Cancer* 2015;15:128
- 4.Liu CH, Huang SC, Chao YJ, Lin XZ, Lee GB. Hemostasis Plug for an Electromagnetic Thermotherapy and Its Application for Liver Laceration. *Ann Biomed Eng* 2015 Jul 3. [Epub ahead of print]
- 5.Chao YJ, Sy ED, Hsu HP, Shan YS. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy. *BMC Surg.* 2014 Sep 25;14:72
- 6.Hou YC, Chao YJ, Tung HL, Wang HC, Shan YS. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. *Cancer.* 2014 Sep 1;120(17):2766-77
- 7.Chao YJ, Shan YS, Zuchini R, Tsai HW, Lin PW, Lee GB, Lin XZ. Successfully Seal Pancreatic End After Thermal Distal Pancreatectomy Using Needle Arrays in Alternating Electromagnetic Fields. *Surg Innov.* 2013 Apr;20(2):150-7
- 8.Chao YJ, Wang CJ, Shan YS. Technical notes: a self-designed, simple, secure, and safe six-loop intracorporeal Pringle's maneuver for laparoscopic liver resection. *Surg Endosc.* 2012; 26: 2681-6
- 9.Huang SC, Chang YY, Chao YJ, Shan YS, Lin XZ, Lee GB. Dual-row needle arrays under an electromagnetic thermotherapy system for bloodless liver resection surgery. *IEEE Trans Biomed Eng.* 2012 Mar;59(3):824-31

Patent

1.專利名稱: 腔內血流控制套件

發明人: 趙盈瑞、賴昱斌、黃聖杰、沈延盛

國別: 中華民國專利證書-發明第 I514987 號

期限: 2016 年 1 月 1 日至 2032 年 7 月 19 日止

2.專利名稱: 微創手術縫合裝置

發明人: 趙盈瑞、陳銘輝、丁育名、黃世樺

國別: 中華民國專利證書-發明第 104141185 號

期限: 2017 年 2 月 21 日至 2035 年 12 月 07 日止

Name: Li-Tzong Chen, MD, Ph.D

Distinguished Investigator and Director (since 2014.08)
National Institute of Cancer Research,
National Health Research Institutes, Tainan,
Taiwan

Adjunct Professor of Internal Medicine
National Cheng Kung University Hospital, Tainan
Kaohsiung Medical University Hospital, Kaohsiung
Taiwan



Contact information:

No. 367, Sheng-Li Road, Tainan 70456, Taiwan

Tel: +886 6 208 3422 ext 65100; Fax +886 6 208 3427; e-mail: leochen@nhri.org.tw

Dr. Chen received his medical training, completed his residency and got his PH.D degree at the Kaohsiung Medical University (KMU), Kaohsiung, Taiwan. He is a qualified medical oncologist and gastroenterologist. Dr. Chen's research interests focus on translation research and experimental therapy to develop new management strategies for gastrointestinal cancers, including gastric cancers, pancreatic cancers, and hepatobiliary cancer. He has participated in design and execution of multiple investigator-initiated phase I-III trials evaluating novel combination chemotherapy regimens, first-in-man cytotoxic agent and molecular targeted agent(s) for these cancers.

Through a multi-center study platform, the Taiwan Cooperative Oncology Group, he has established the use of front-line antibiotics in early-stage, *H. pylori*-positive diffuse large B cell lymphoma of the stomach, explored the role of adjuvant anti-viral therapy interferon- α 2b *versus* observation alone and prophylactic *versus* therapeutic anti-HBV nucleoside in hepatitis virus-related hepatocellular carcinoma after surgical resection, developed novel triplet chemotherapy for advanced pancreatic cancer.

Because of his role in phase I studies and subsequent contributions, Dr. Chen was the co-chair of the global phase III trial of everolimus in sorafenib-failure hepatocellular carcinoma (EVOLVE-1, *JAMA* 2015) and the corresponding author of NAPOLI-1 trial investigating nanoliposomal irinotecan in metastatic pancreatic cancer with previous gemcitabine-based therapy (*Lancet* 2016).

Recent publications:

1. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartzmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, **Chen LT***, NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet* 2015 Nov 22 [Epub ahead of print]
2. Liu TW, **Chen LT***. S-1 and leucovorin for gastric cancer: How far can it go? *Lancet Oncol.* 2015 Nov 27 (comment) [Epub ahead of print]
3. Zhu AX, Kudo M, Assenat E, Cattani S, Kang YK, Lim HY, Poon RTP, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, **Chen LT#**. Everolimus for advanced hepatocellular carcinoma after failure of sorafenib: Results from the randomized, phase 3 EVOLVE-1 study. *JAMA* 2014;213(1):57-67.
4. Shen L, Shan YS, Hu HM, Price T, Sirohi B, Yeh KH, Yang YH, Sano T, Yang KH, Zhang XT, Park SR, Fujii M, Kang YK, **Chen LT***. Management of gastric cancer in Asia: resource-stratified guidelines. *Lancet Oncology* 2103; 14: e535–47
5. Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJM, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MTL, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL, **Chen LT**, Tsai KC. A gene expression signature of epithelial tubulo-genesis and a role for ASPM in pancreatic tumor progression. *Gastroenterology* 2013 Nov;145:1110-20
6. Hsueh YS, Yen CC, Shih NY, Chiang NJ, Li CF, **Chen LT***. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. *Autophagy* 2013 Feb 1;9(2):220-33.
7. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh G, **Chen LT***. A multinational phase 2 study of nanoliposomal irinotecan (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. *Br J Cancer* 2013 Aug 20;109:920-5
8. Shiah HS, Chen CY, Lin YJ, Su WC, Chang JY, Winkler R, Whang-Peng J, Lin PW, Huang JD*, **Chen LT***. Randomized clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. *Aliment Pharm Ther* 2013;37;62-74
9. SH Kuo, KH Yeh, MS Wu, CW Lin, PN Hsu, HP Wang, **LT Chen***, AL Cheng*. *H. pylori* eradication therapy is effective in the treatment of early-stage *H. pylori*-positive gastric diffuse large B-cell lymphomas. *Blood* 2012 Dec;119:4838-4844
10. **Chen LT***, Chen MF*, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ*. Long-term results of a randomization trial of adjuvant interferon alpha-2b in virus-related hepatocellular carcinoma with curative resection. *Ann Surg* 2012 Jan;255(1):8-17

Curriculum vitae

Name: Li-Yuan Bai, M.D., M.M.S., Ph.D.

E-mail: lybai6@gmail.com

Current Position:

Aug. 2005 – present : Doctor, Division of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan

Feb. 2017 – present: Professor, China Medical University

Education and Board:

Sep. 1987 – Jun. 1994: School of Medicine, National Yang-Ming University, Taipei, Taiwan

Mar. 1997: Certification of Educational Commission for Foreign Medical Graduates, USA

Oct. 2001: Certified Doctor of Internal Medicine

Nov. 2003: Certified Doctor of Medical Oncology

Feb. 2004: Member of Taiwan Academy of Hospice Palliative Medicine

Nov. 2004: Certified Doctor of Hematology

Jul. 2007: Master of Medical Science, Graduate Institute of Medical Science, China Medical University, Taichung, Taiwan

Jun. 2011: Ph.D., Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

Previous Employments: Jun. 1998 - Dec. 2004: Resident doctor, Department of Medicine, Taipei Veterans General Hospital (VGH), Taipei, Taiwan

Dec. 2004 – Jul. 2005: Visiting staff, Department of Medicine, Yilan Hospital

Mar. 2008 – May. 2009: Visiting scholar at College of Pharmacy, The Ohio State University, Columbus, OH, USA

Publications (selective after 2015)

1. Weng JR*, Bai LY, Ko HH, Tsai YT. Cyclocommunol induces apoptosis in human oral squamous cell carcinoma partially through a Mcl-1-dependent mechanism. *Phytomedicine* 2018 Jan 15;39:25-32.
2. Yoon-Koo Kang, Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Li-Tzong Chen. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5.
3. Weng JR*, Bai LY, Lin WY. Identification of a Triterpenoid as a Novel PPAR γ Activator Derived from Formosan Plants. *Phytother Res*. 2017 Nov;31(11):1722-1730. doi: 10.1002/ptr.5900.
4. Bai LY, Chiu CF, Chiu SJ, Chu PC, Weng JR. FTY720 induces autophagy-associated apoptosis in human oral squamous carcinoma cells, in part, through a reactive oxygen species/Mcl-1-dependent mechanism. *Sci Rep* 2017 Jul 17;7(1):5600. doi: 10.1038/s41598-017-06047-9.
5. Tsai WC, Bai LY, Chen YJ, Chu PC, Hsu YW, Sargeant AM, Weng JR*. OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling. *Oncotarget* 2017 Apr 25;8(17):29233-29246. doi: 10.18632/oncotarget.16450

6. Weng JR*, Bai LY, Lin WY, Chiu CF, Chen YC, Chao SW, Feng CH. A Flavone Constituent from *Myoporum bontioides* Induces M-Phase Cell Cycle Arrest of MCF-7 Breast Cancer Cells. *Molecules* 2017 Mar 15;22(3). pii: E472.
7. Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Tse-Yen Yang, Aaron M. Sargeant, Li-Yuan Bai*. Palliative gastrectomy prolongs survival of metastatic gastric cancer patients with normal preoperative CEA or CA19-9 values: a retrospective cohort study. *Gastroenterol Res Pract* 2016;2016:6846027.
8. Chiu CF, Weng JR, Jadhav A, Wu CY, Sargeant AM, Bai LY*. T315 decreases acute myeloid leukemia cell viability through a combination of apoptosis induction and autophagic cell death. *Int J Mol Sci* 2016 Aug 15;17(8). pii: E1337.
9. Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Aaron M. Sargeant, Su-Peng Yeh, Li-Yuan Bai*. The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation. *Springerplus* 2016 Jun 16;5(1):728.
10. Wu CH, Bai LY, Tsai MH, Chu PC, Chiu CF, Chen MY, Chiu SJ, Chiang JH, Weng JR*. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-A drug repurposing strategy. *Sci Rep.* 2016 Jun 9;6:27540. doi: 10.1038/srep27540.
11. Bai LY, Chiu CF, Chu PC, Lin WY, Chiu SJ, Weng JR*. A triterpenoid from wild bitter melon inhibits breast cancer cells. *Sci Rep.* 2016 Mar 1;6:22419. doi: 10.1038/srep22419.
12. Bai LY, Chiu CF, Kapuriya NP, Shieh TM, Tsai YC, Wu CY, Sargeant AM, Weng JR*. BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest. *Eur J Pharmacol* 2015 Dec;769:287-296.
13. Chiou TJ, Chang YF, Wang MC, Kao CW, Lin HY, Chen TY, Hsueh EJ, Lan YJ, Sung YC, Lin SF, Bai LY, Chen CG*. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura. *Transl Res* 2015 Sep 30. pii: S1931-5244(15)00329-1. doi: 10.1016/j.trsl.2015.09.005.
14. Li-Yuan Bai, Chang-Fang Chiu, Shih-Jiuan Chiu, Yu-Wen Chen, Jing-Lan Hu, Chia-Yung Wu, and Jing-Ru Weng*. Alphitolic acid, an anti-inflammatory triterpene, induces apoptosis and autophagy in oral squamous cell carcinoma cells, in part, through a p53-dependent pathway. *J Funct Foods* 2015;18:368-78.
15. Hung-Jen Chen, Kuo-Yang Huang, Guan-Chin Tseng, Li-Hsiou Chen, Li-Yuan Bai, Shinn-Jye Liang*, Chih-Yen Tu, Richard W. Light. Diagnostic pitfalls of discriminating lymphoma-associated effusions. *Medicine (Baltimore)* 2015 May;94(17):e800.
16. Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT*; on behalf of the Taiwan Cooperative Oncology Group. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. *Ann Oncol* 2015 May;26(5):943-9.
17. Tzu-Ting Chen, Chang-Fang Chiu, Tse-Yen Yang, Ching-Chan Lin, Aaron M. Sargeant, Su-Peng Yeh, Yu-Min Liao, Li-Yuan Bai*. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. *Leuk Res* 2015;39:151-6. (corresponding)

第十二屆胰臟癌國際研討會暨林炳文教授紀念演講會

報 名 表

身份類別	<input type="checkbox"/> 主治醫師	<input type="checkbox"/> 住院醫師	<input type="checkbox"/> 其它
姓 名			
參加研討會日期	<input type="checkbox"/> 7/5	<input type="checkbox"/> 7/6	
服務單位/部門			
行動電話			
e-mail			
午餐 (7/6 Lunch symposium)	<input type="checkbox"/> 用餐(葷)	<input type="checkbox"/> 用餐(素)	<input type="checkbox"/> 不用餐

報名方式

* 傳真報名：請填妥報名表後，將報名表傳真至(06)2766676。

* E-mail：ncku013@hotmail.com

注意事項

* 場地名額有限，額滿為止，請於6月1日以前完成報名手續。

* 聯絡人：林小姐 (06) 2353535#3116



交通資訊：


- ① 搭高鐵至左營站轉乘高雄捷運（小港方向）至後驛站
- ② 搭台鐵於高雄站前站下車轉搭高雄捷運（岡山方向）至後驛站
- ③ 於台鐵新左營站下車轉搭高雄捷運（小港方向）至後驛站。於 2 號出口出站，沿察哈爾一街步行約 10 分鐘，或搭乘捷運接駁公車紅 29、紅 30，於「高醫(高雄醫學大學)站」下車抵達啟川大樓。

自行開車：

7/5 需付費：高雄醫學大學學校平面停車場（1 日約 300 元）

7/6

1. 免費停車：高雄醫學大學學校地下停車場 B2-B3（入場停車前表明參加夏季會）
2. 需付費：高醫院區地下停車場



運具
Transfer to

- 機場
Airport
- 高鐵
THSR
- 台鐵
TRA
- 輕軌
LRT
- 港口
Harbor

營運路線
Operation Lines

- 紅線 (南岡山-小港)**
Red Line (Gangshan South - Siaoang)
- 橘線 (西子灣-大寮)**
Orange Line (Sizihwan - Daliao)
- 輕軌 (籬仔內-哈瑪星)**
LRT (Lizihnei- Hamasen)
- 輕軌 (暫不營運)**
LRT (Under construction)

圖例
Legend

- 一般站**
General Station
- 交會站**
Interchange Station
- 端點站**
Terminal Station
- 路線記號
Line Symbol
- 路線顏色
Line Color
- 車站編號
Station Number

